Condition: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Leukemia (SLL) · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
This description comes directly from the study's public registry record.
Andrew Zelenetz, MD, PhD · 212-639-2656 · zeleneta@mskcc.org
Anthony Mato, MD · 212-639-8596
Always discuss trial participation with your own doctor first.
| Northwestern University | Evanston, Illinois, United States | Recruiting |
| Massachusetts General Hospital (Data Collection and Specimen Analysis) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering at Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03824483